MedTrace Logo

A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants

NCT02595268 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-01-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of steady-state concentrations of JNJ-63623872 on the single-dose pharmacokinetics of pitavastatin in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

Pitavastatin

Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.

DRUG

JNJ-63623872

Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595268 on ClinicalTrials.gov